SPR 965

Drug Profile

SPR 965

Alternative Names: SPR965

Latest Information Update: 12 Feb 2016

Price : $50

At a glance

  • Originator Sphaera Pharma
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 20 Apr 2015 Preclinical trials in Multiple myeloma in Singapore (PO) before April 2015
  • 08 Apr 2014 Preclinical trials in Solid tumours in Singapore (PO) before April 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top